TITAN Medical Inc.
120 Adelaide Street West, Suite 2400
P.O. Box 23
Toronto
Ontario
M5H 1T1
Canada
Tel: 416-368-4397
Fax: 416-368-1608
Website: http://www.titanmedicalinc.com/
Email: info@titanmedicalinc.com
200 articles about TITAN Medical Inc.
-
Titan Medical Announces Closing of US$1.2 Million Registered Direct Offering
3/27/2020
Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce today that it closed its previously announced registered direct offering for the purchase and sale of 7,000,000 common shares of the Company (the “Common Shares”) at a purchase price of US$0.17
-
Titan Medical Expands and Strengthens Global Intellectual Property Portfolio With Issuance of Robotic Surgery Patents
3/26/2020
Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), announces that its global intellectual property portfolio has increased to 49 issued patents and 86 patent applications, including the recent granting and filing of patent applications directed at innovative robotic surgery technologies.
-
Titan Medical Announces US$1.2 Million Registered Direct Offering
3/25/2020
Titan Medical Inc. announce today that it has entered into definitive agreements with institutional investors that provide for the purchase and sale of 7,000,000 common shares of the Comp
-
Titan Medical Announces Departure of Director Domenic Serafino
2/11/2020
Feb. 11, 2020 13:12 UTC TORONTO--( BUSINESS WIRE )-- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI) , a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), announces that Domenic (Dom) Serafino has resigned as a Director of the Company. Titan has begun the process of seeking qualified candidates to fill this vacancy. In tendering his resignation t
-
Titan Medical Issues Letter to Shareholders - Feb. 3, 2020
2/3/2020
Titan Medical Inc., a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery, announces that David McNally, President & CEO, has issued a letter to shareholders.
-
Titan Medical Receives ISO 13485 Certification, Provides Update on Fourth Quarter Milestones
1/27/2020
Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), today announced receipt of ISO 13485 Certification from a European Notified Body following completion of audits of the Company’s quality system and related documentation.
-
Titan Medical and Cambridge Design Partnership Announce Expanded Engagement for Robotic Instrument Development
1/6/2020
Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), and Cambridge Design Partnership Ltd. (“CDP”), today announce an expanded engagement in respect of the instrument development program for Titan’s single-port robotic surgical system.
-
Titan Medical Announces New Common Share Purchase Agreement With Aspire Capital Fund of up to US$35 Million
12/23/2019
Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that it has entered into a Common Share Purchase Agreement (the “Agreement”) with Aspire Capital Fund, LLC
-
Titan Medical Confirms Receipt of Deficiency Notices From Nasdaq
12/4/2019
Nasdaq Rule 5550(a)(2) requires the Shares to maintain a minimum bid price of US$1.00 per Share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the Shares is below US$1.00 for a period of 30 consecutive business days.
-
Titan Medical to Participate in Two Investment Conferences in December 2019
11/21/2019
Titan Medical Inc. announced that Company management will be participating in two upcoming investor conferences.
-
Titan Medical Reports Third Quarter 2019 Financial Results
11/14/2019
All financial results are prepared in accordance with International Financial Reporting Standards (“IFRS”) and are reported in U.S. dollars, unless otherwise stated.
-
Titan Medical Determines Not to Proceed with Public Offering
11/7/2019
The Company has made this decision based on its assessment of market conditions, and intends to pursue alternative financing options.
-
Titan Medical Announces Filing of Final Prospectus - Nov. 1, 2019
11/1/2019
Titan Medical Inc. is pleased to announce that it has filed and been receipted for a final short form prospectus in connection with the previously announced marketed offering of units of the Company at a price of US $0.45 per Unit for minimum gross proceeds of US $15,000,000 and maximum gross proceeds of US $25,000,000.
-
Titan Medical Announces Pricing of Marketed Offering
10/25/2019
Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce today that it has priced its previously announced marketed offering (the “Offering”) of units of the Company (the “Units”).
-
Titan Medical Announces Filing of Amended and Restated Preliminary Prospectus and Withdrawal of Previously Published Milestones
10/15/2019
The A&R Preliminary Prospectus and Registration Statement are subject to completion and amendment.
-
Titan Medical Continues to Market Offering of Units - Oct. 1, 2019
10/1/2019
Titan Medical Inc announced on Monday, September 23, 2019 that it had filed and been receipted for a preliminary short form prospectus with securities regulators in the provinces of Ontario, British Columbia and Alberta.
-
Titan Medical Continues to Market Offering of Units
9/24/2019
Titan had also filed a corresponding registration statement on Form F-10 with the United States Securities and Exchange Commission under the U.S.-Canada Multijurisdictional Disclosure System.
-
Titan Medical Announces Overnight Marketed Offering of Units - Sept. 23, 2019
9/23/2019
Titan Medical Inc. announced that it has filed and been receipted for a preliminary short form prospectus with securities regulators in the provinces of Ontario, British Columbia and Alberta.
-
Titan Medical Announces Change to Presentation Time at H.C. Wainwright Conference
9/6/2019
Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that management’s presentation at the H.C. Wainwright 21st Annual Global Investment Conference has been moved to 2:35 p.m. Eastern time on Tuesday, September 10.
-
Titan Medical Strengthens Robotic Surgery U.S. Patent Portfolio With Grant for Surgical Imaging Technology
9/3/2019
Company’s head of intellectual property recognized by Intellectual Asset Management as a global IP strategy leader for fifth consecutive year